Compare Biocon Ltd with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs JUBILANT LIFE SCIENCES - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON JUBILANT LIFE SCIENCES BIOCON /
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 19.4 14.3 135.5% View Chart
P/BV x 3.0 1.7 179.6% View Chart
Dividend Yield % 0.4 0.9 43.3%  

Financials

 BIOCON    JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    BIOCON
Mar-18
JUBILANT LIFE SCIENCES
Mar-19
BIOCON /
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,188898 132.3%   
Low Rs305618 49.4%   
Sales per share (Unadj.) Rs68.7572.0 12.0%  
Earnings per share (Unadj.) Rs7.636.2 20.8%  
Cash flow per share (Unadj.) Rs14.059.5 23.5%  
Dividends per share (Unadj.) Rs1.004.50 22.2%  
Dividend yield (eoy) %0.10.6 22.6%  
Book value per share (Unadj.) Rs86.3301.9 28.6%  
Shares outstanding (eoy) m600.00159.28 376.7%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.91.3 820.0%   
Avg P/E ratio x98.920.9 472.6%  
P/CF ratio (eoy) x53.412.7 419.7%  
Price / Book Value ratio x8.62.5 344.5%  
Dividend payout %13.212.4 106.6%   
Avg Mkt Cap Rs m447,900120,694 371.1%   
No. of employees `0006.12.4 257.3%   
Total wages/salary Rs m9,31119,260 48.3%   
Avg. sales/employee Rs Th6,705.838,120.6 17.6%   
Avg. wages/employee Rs Th1,514.28,058.4 18.8%   
Avg. net profit/employee Rs Th736.92,414.3 30.5%   
INCOME DATA
Net Sales Rs m41,23491,108 45.3%  
Other income Rs m2,062357 576.9%   
Total revenues Rs m43,29691,466 47.3%   
Gross profit Rs m8,29117,390 47.7%  
Depreciation Rs m3,8513,709 103.8%   
Interest Rs m6152,198 28.0%   
Profit before tax Rs m5,88711,840 49.7%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m1,5693,268 48.0%   
Profit after tax Rs m4,5315,770 78.5%  
Gross profit margin %20.119.1 105.3%  
Effective tax rate %26.727.6 96.6%   
Net profit margin %11.06.3 173.5%  
BALANCE SHEET DATA
Current assets Rs m41,48645,848 90.5%   
Current liabilities Rs m21,41320,897 102.5%   
Net working cap to sales %48.727.4 177.8%  
Current ratio x1.92.2 88.3%  
Inventory Days Days6457 112.6%  
Debtors Days Days9451 184.9%  
Net fixed assets Rs m50,66165,498 77.3%   
Share capital Rs m3,000159 1,883.2%   
"Free" reserves Rs m48,80847,930 101.8%   
Net worth Rs m51,80848,089 107.7%   
Long term debt Rs m17,89842,429 42.2%   
Total assets Rs m99,897114,685 87.1%  
Interest coverage x10.66.4 165.5%   
Debt to equity ratio x0.30.9 39.2%  
Sales to assets ratio x0.40.8 52.0%   
Return on assets %5.26.9 74.1%  
Return on equity %8.712.0 72.9%  
Return on capital %9.612.4 77.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05812,422 97.1%   
Fx outflow Rs m7,34817,227 42.7%   
Net fx Rs m4,710-4,805 -98.0%   
CASH FLOW
From Operations Rs m6,62111,215 59.0%  
From Investments Rs m-6,840-10,118 67.6%  
From Financial Activity Rs m-2,3976,574 -36.5%  
Net Cashflow Rs m-2,6127,612 -34.3%  

Share Holding

Indian Promoters % 40.4 45.6 88.6%  
Foreign collaborators % 20.6 3.5 588.6%  
Indian inst/Mut Fund % 8.4 8.7 96.6%  
FIIs % 10.7 21.2 50.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 21.1 94.3%  
Shareholders   109,995 23,815 461.9%  
Pledged promoter(s) holding % 0.0 15.9 0.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  NATCO PHARMA  

Compare BIOCON With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Oct 18, 2019 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS